BTG International, Inc.
$1.2M 757 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
DiaSorin Inc.
DiaSorin Inc. reported $1,183,686.17 across General Payments, Research, and Ownership to 37 physicians and teaching hospitals across 65 transactions.
- $1.2M Above-median payer
- All-tracks total
- 65 Below-median volume
- Transactions
- 37 Below-median reach
- Recipients
- +$23.3K
- General Payments vs PY2023
DiaSorin Inc. reported $1,183,686.17 across all CMS Open Payments tracks (General + Research + Ownership) to 37 physicians and teaching hospitals in Program Year 2024 - ranking #583 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $371,531.53, averaging $32.0K per recipient.
How DiaSorin Inc.'s $1.2M all-tracks total breaks down
DiaSorin Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
21/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer diasorin-inc DiaSorin Inc.
$1.2M · #583/1,925 · 0.0% industry · PY2024
- TOT $1.2M
- RANK #583
- SHARE 0.0%
- TXN 65
- RCP 37
- CAT 5
- GEN $371.5K
- ΔGEN +$23.3K
- TOP1 74.0%
- PY 2024
Volume peers
Nearest volume peer: BTG International, Inc. ($1.2M)
DiaSorin Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
DiaSorin Inc.'s CMS-reported General Payments increased by $23.3K (+6.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: DIASORIN INC.PY2023: DIASORIN INC.PY2024: DiaSorin Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $348,226.02
- PY2024
- $371,531.53
What the Data Shows for DiaSorin Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For DiaSorin Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 5 general-payment categories charted below, "Consulting Fee" is the largest at $302.0K across 12 transactions, 81.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
DiaSorin Inc. made 5 types of general payments. "Consulting Fee" is the largest category at $302.0K, 81.3% of General Payments.
DiaSorin Inc. reports 5 general-payment categories - the top three are Consulting Fee (81.3%), Compensation for Services Other Than Consulting (15.2%), and Travel and Lodging (1.7%). The remaining 2 categories make up 1.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How DiaSorin Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $302.0K | 12 | 81.3% |
| Compensation for Services Other Than Consulting | $56.6K | 11 | 15.2% |
| Travel and Lodging | $6.2K | 9 | 1.7% |
| Compensation for Faculty or Speaker (Medical Education) | $6.0K | 2 | 1.6% |
| Food and Beverage | $715.67 | 3 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $340,664.58 (91.7%) of $371,531.53 in this company's General Payments records across 11 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for DiaSorin Inc.
The five named recipients with the highest reported General Payments from this company
- 1
David Engman
$274,973.33 across 5 reported transactions
- 2
Inspira Medical Center Vineland
$21,847.50 across 5 reported transactions
- 3
Cleveland Clinic Hospital
$15,860.00 across 1 reported transactions
- 4
David Hale
$15,633.75 across 12 reported transactions
- 5
St. Lukes Regional Medical Center
$12,350.00 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
DiaSorin Inc.'s spend rank (#583 of 1,925, top 30% by spend) and concentration rank (#296 of 1,838, top 16% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Inpeco North America, Inc : $7.5K total payments, HHI 5612
- FFF Enterprises, Inc. : $3.6K total payments, HHI 5610
- Retropsoas Technologies, LLC : $14.6K total payments, HHI 5606
- Ipsen Biopharm Limited : $13.1K total payments, HHI 5603
- BlueRock Therapeutics LP : $405.9K total payments, HHI 5593
- Nidek Co., Ltd. : $29.8K total payments, HHI 5592
- DiaSorin Inc. (this company) : $371.5K total payments, HHI 5574
- Bavarian Nordic A/S : $68.0K total payments, HHI 5563
- Mindera Corp : $7.5K total payments, HHI 5556
- Ferring International Pharmascience Center US : $282.61 total payments, HHI 5546
- Eko Health, Inc. : $115.5K total payments, HHI 5521
- Maquet Critical Care AB : $2.6K total payments, HHI 5476
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as DiaSorin Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about DiaSorin Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with DiaSorin Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Organ Recovery Systems, Inc.
$1.2M 84 recipients
Compare payment profiles
Catalyst Pharmaceuticals, Inc.
$1.2M 8,453 recipients
Compare payment profiles
GenBioPro, Inc.
$1.2M 15 recipients
Compare payment profiles
The North Carolina Mutual Wholesale Drug Company Inc
$1.2M 0 recipients
Compare payment profiles
New Wave Endo-Surgical Corp.
$1.2M 1 recipients
Compare payment profiles
Put this to use
DiaSorin Inc. ranks #583 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where DiaSorin Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just DiaSorin Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.